Feature | May 12, 2014

Maquet Recalls Intra-Aortic Balloon Pumps Due to Potential Failure of Power Supply

Company says recall affects 12,360 IABP units sold globally

IABP, Datascope, Maquet, FDA recall

May 12, 2014 — Datascope Corp./Maquet initiated a voluntary worldwide field correction of some of its intra-aortic balloon pumps (IABPs) due to a potential mechanical failure of the fan assembly associated with the power supply. All customers that may have an IABP affected by this field correction have been notified. The company says there are about 12,360 affected units sold globally.

The firm received 106 reports of device malfunctions, which caused one death, involving its system 98/98XT, CS100, CS100i and CS300 IABPs. The firm determined that the fan assembly for the affected IABPs could contain a misshapen retaining ring. This retaining ring could separate within the fan assembly, causing the fan to stop rotating. This could result in the power supply overheating and the IABP would shut down without any warning. This device failure would cause the balloon to stop inflating and deflating. It may result in decreased blood flow to the heart and the rest of the body, difficulty in weaning the patient from cardiopulmonary bypass, and clotting or blockage of blood vessels to the intestines, kidneys, or legs. The possible long range consequences of this include organ injury or tissue damage, possibly leading to patient death.

The recalled systems were sold under the Datascope Corp. and include system 98/98XT (part numbers: 0998-00-0446-xx, 0998-UC-0446-xx, 0998-00- 0479-xx and 0998-UC-0479-xx), CS100/CS100i (Part Numbers: 0998-00-3013-xx, 0998-UC-3013-xx, 0998-UC-0446Hxx and 0998-UC-0479Hxx) and CS300 (part numbers:0998-00-3023-xx and 0998-UC-3023-xx).

The IABP is an electromechanical system used to inflate and deflate an intra-aortic balloon to provide temporary support to the left ventricle via the principle of counter pulsation.

Between Jan. 1, 2003, and June 30, 2011, specific System 98/98XT, CS100/CS100i and CS300 IABPs were manufactured with an affected fan assembly, or may have received an affected fan assembly during an upgrade/service of the IABP in the field. The affected IABP units were distributed in the United States and worldwide (in more than 100 countries). The affected IABP's can be identified by part and serial number. Each Maquet service representative has a list of the affected serial numbers and will check each affected part during the corrective action.

The affected system 98/98XT, CS100, CS100i and CS300 IABPs involved in the field correction can be used while waiting for parts and service. Customers should adhere to the instructions for use when using an affected IABP.

The U.S. Food and Drug Administration (FDA) has classified this action as a Class 1 recall. FDA defines Class 1 recalls as, "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." To date, there have been no reported patient injuries or deaths related to the power supply malfunction.

The corrective action associated with this recall is to provide a replacement fan assembly to all IABPs containing an affected fan assembly. A Maquet service representative will contact those facilities with affected IABP's to schedule corrective action and document this corrective action during a visit to the customer.

For additional information regarding this field correction, please contact the Technical Support Department at (800) 777-4222 and press 3 (Monday through Friday 8 a.m. – 6 p.m. EST).

For more information: www.fda.gov/MedicalDevices/NewsEvents/News/default.htm

Related Content

the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock
Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Sponsored Content | Videos | Hemodynamic Support Devices| March 21, 2017
The Abiomed Impella percutaneous ventricular assist devices (pVAD) offer between 2.5 and 5 liters of flow per minute
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Abiomed, Impella heart pump, 50,000 patients treated, United States, milestone
News | Ventricular Assist Devices (VAD)| February 24, 2017
Abiomed Inc. announced that it has supported more than 50,000 patients in the U.S. with its Impella line of heart pumps...
Jaheim Whigham, Lurie Children's Hospital of Chicago, Syncardia 50cc Total Artificial Heart, youngest patient

At 11 years old, Jaheim Whigham (center) is the youngest and smallest patient to receive the 50cc SynCardia temporary Total Artificial Heart. (Photo: Jan Terry, Ann & Robert H. Lurie Children's Hospital of Chicago)

News | Congenital Heart| January 31, 2017
To save the life of an 11-year-old boy, Ann & Robert H. Lurie Children’s Hospital of Chicago has become the first...
Overlay Init